Alpha-galactosylceramide (α-GalCer) treatment decreases the infiltration of inflammatory cells into the kidney. Representative images of (a) F4/80-stained and (b) CD3-stained kidney slices in the vehicle (left) and α-GalCer (right) groups. In each panel, arrows indicate F4/80 or CD3-positive areas. The percentages of the (c) F4/80-positive area and (d) CD3-positive area in each group (vehicle group; n = 5, α-GalCer group; n = 7). *p < 0.05 compared with the vehicle group.